Swedish Orphan Biovitrum Publishes Annual Report
Published: Apr 05, 2013
STOCKHOLM, SWEDEN--(Marketwired - April 05, 2013) -
Swedish Orphan Biovitrum AB (Sobi) today published its Annual Report for 2012, themed "Building value for patients, partners and shareholders", on the company's website, www.sobi.com.
The report encompasses the company's approach to keeping the patient journey - from diagnosis and treatment, to on-going disease management and long-term outcomes - at the centre of how it prioritises its capabilities and investments. By creating and maintaining a dialogue with key stakeholders (patients organizations, physicians, governments and payers), Sobi seeks to ensure that treatments are delivered in a sustainable way. Sobi refers to this approach as Patient and Customer Centric commercialisation.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (EUR 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
Sobi press release April 5, 2013 in pdf version: http://hugin.info/134557/R/1690373/554932.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
For more information - not for publication
Head of Communications
T: +46 70 410 71 80
Vice President, Head of Investor Relations
T: +1 347 224 0819